BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
BioNTech SE (Nasdaq: BNTX, BioNTech) and Kite, a Gilead Company (Nasdaq: GILD, Kite) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kites solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD.
- BioNTech SE (Nasdaq: BNTX, BioNTech) and Kite, a Gilead Company (Nasdaq: GILD, Kite) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kites solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD.
- To support its growing cell therapy pipeline, BioNTech plans to further invest in the site including hiring additional personnel.
- Under the terms of the agreement, Kite will receive a one-time upfront payment from BioNTech to purchase Kites individualized solid tumor neoantigen TCR discovery platform as well as the Gaithersburg R&D and clinical manufacturing facility.
- Kites new manufacturing facility in Frederick, MD for commercial production of CAR T-cell therapy is not part of the purchase agreement.